Form 4: Evolent Health's General Counsel, Jonathan Weinberg, Reports Changes in Beneficial Ownership
SEC Form 4 Filing
Jonathan Weinberg, General Counsel of Evolent Health, reports transactions involving Class A Common Stock, including acquisitions, disposals, and vesting of restricted stock units and performance-based share units.
Summary
- On March 1, 2025, Jonathan Weinberg, General Counsel of Evolent Health, had shares of Class A Common Stock withheld to cover tax obligations upon vesting of restricted stock units at a price of $8.99 per share, totaling 8,808 shares.
- On March 3, 2025, Mr. Weinberg acquired 65,470 shares of Class A Common Stock through restricted stock units granted under the company's 2015 Omnibus Incentive Compensation Plan.
- These restricted stock units vest in three tranches: 34% on March 3, 2026, and 33% on March 3, 2027, and March 3, 2028.
- Also on March 3, 2025, Mr. Weinberg acquired 10,640 shares of Class A Common Stock upon settlement of performance-based share units (PSUs) awarded on March 1, 2022, which vested on December 31, 2024, after the Compensation Committee certified the achievement of performance metrics.
- Additionally, on March 3, 2025, 3,544 shares of Class A Common Stock were withheld to satisfy tax obligations upon settlement of these performance-based share units at a price of $8.77 per share.
- Following these transactions, Mr. Weinberg's total beneficial ownership of Class A Common Stock is 230,785 shares.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing reflecting standard compensation practices. The vesting of PSUs suggests performance targets were met, which is mildly positive.
Positives
- The vesting of restricted stock units and performance-based share units indicates that Mr. Weinberg is incentivized to contribute to the long-term success of Evolent Health.
- The achievement of performance metrics leading to the settlement of PSUs suggests that the company is meeting its goals.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and alignment with shareholder interests.
Comparison to Industry Standards
- Monitoring insider transactions is a common practice in the healthcare industry, with companies like UnitedHealth Group (UNH) and CVS Health (CVS) also subject to similar reporting requirements.
- The vesting schedules for restricted stock units are typical for executive compensation packages, often designed to incentivize long-term performance and retention, similar to practices observed at companies like Humana (HUM) and Centene (CNC).
Stakeholder Impact
- Shareholders can use this information to understand the alignment of management's interests with their own.
- Employees may be interested in the details of the equity compensation plans.
Key Dates
| Date | Description |
|---|---|
| 03/01/2022 | Date performance-based share units (PSUs) were awarded to the reporting person. |
| 12/31/2024 | Date the shares underlying the PSU award vested at the conclusion of the performance period. |
| 03/01/2025 | Date of transaction involving withholding of shares for tax obligations. |
| 03/03/2025 | Date of transactions involving grant of restricted stock units and settlement of performance-based share units. |
| 03/04/2025 | Date of signature of the reporting person. |
| 03/03/2026 | Date of first vesting tranche (34%) for restricted stock units. |
| 03/03/2027 | Date of second vesting tranche (33%) for restricted stock units. |
| 03/03/2028 | Date of final vesting tranche (33%) for restricted stock units. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.